CELL-BASED CANCER IMMUNOTHERAPY: FROM ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY TO DENDRITIC CELLS THERAPEUTIC VACCINATION

Abstract

In recent years, cancer immunotherapy has been shown as a promising cancer treatment strategy for cancer treatment. Antibody-dependent cellular cytotoxicity (ADCC) uses tumour-antigen specific antibodies to identify target cells before the infusion of effector cells to elicit anti-tumour effects. Recently, researchers found that γδT cells have similar receptors expression and anti-tumor functions with Natural Killer (NK) cells. Therefore, we aim to study the potential of γδT cells as an alternative effector cell type to NK cells for use in ADCC.

Cancer stem cells (CSC) are widely attributed for cancer relapse. CSCs are reported to overexpress Oct4 and Sox2 genes to maintain stemness and can be used as antigens for CSC targeting. We attempt to generate DC vaccines targeting Oct4 and Sox2 genes through Baculovirus-mediated full-length gene delivery of Oct4 and Sox2. This DC vaccine would be capable of producing Oct4 and Sox2 antigen targeting cytotoxic T lymphocytes for CSC targeting.